Hello,
What is OPNG
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect pathogens in positive blood cultures. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.
News
Looking into the current session, OpGen Inc. (NASDAQ: OPGN) shares are trading at $2.13, after a 7.03% spike. Moreover, over the past month, the stock went up by 4.93%, but in the past year, fell by 74.82%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session.
The stock is currently higher from its 52 week low by 913.27%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with Diagnostics & Research stocks, and capitalize on the lower share price observed over the year.
My Thoughts For You
Call me crazy, I don't mind but you may regret not getting in on this opportunity. Like the last chart I published, I recognized that after a huge dump the price action will retrace between 61.8% and 78.6%. This stock is definitely undervalued and the bottom is behind us now.
Good Luck, Cheers!
Be sure to comment, follow, like, and check out my profile for more trade ideas!
What is OPNG
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect pathogens in positive blood cultures. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.
News
Looking into the current session, OpGen Inc. (NASDAQ: OPGN) shares are trading at $2.13, after a 7.03% spike. Moreover, over the past month, the stock went up by 4.93%, but in the past year, fell by 74.82%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session.
The stock is currently higher from its 52 week low by 913.27%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with Diagnostics & Research stocks, and capitalize on the lower share price observed over the year.
My Thoughts For You
Call me crazy, I don't mind but you may regret not getting in on this opportunity. Like the last chart I published, I recognized that after a huge dump the price action will retrace between 61.8% and 78.6%. This stock is definitely undervalued and the bottom is behind us now.
Good Luck, Cheers!
Be sure to comment, follow, like, and check out my profile for more trade ideas!
